Home > News > Clinical Data Presented at ESMO
November 8th, 2004
Clinical Data Presented at ESMO
Abstract:
ACLARA BioSciences today announced that Sharat Singh, Ph.D., ACLARA's Chief Technical Officer, presented data from a pilot clinical trial demonstrating the ability of ACLARA's eTag(TM) assays to correctly differentiate responders from non-responders to Herceptin(R) treatment in patients with breast cancer. These data, subject to confirmation in larger, trials, suggest that the eTag System may be more accurate than the current standard at differentiating responders from non-responders to this widely used targeted therapy.
Source:
ACLARA BioSciences
Bookmark:
| Related News Press |
Possible Futures
Rice research could make weird AI images a thing of the past: New diffusion model approach solves the aspect ratio problem September 13th, 2024
New discovery aims to improve the design of microelectronic devices September 13th, 2024
Nanomedicine
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
Announcements
New discovery aims to improve the design of microelectronic devices September 13th, 2024
New method in the fight against forever chemicals September 13th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||